1572P - Current and future next generation sequencing usage in European molecular oncology diagnostics

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Sarcoma
Presenter Christopher Whitten
Citation Annals of Oncology (2016) 27 (6): 526-544. 10.1093/annonc/mdw392
Authors C.M. Whitten1, A. Thum2, T. Blass2
  • 1Ivd, dii Healthcare, 04107 - Leipzig/DE
  • 2Ivd, dii Healthcare, Leipzig/DE



The integration of next generation sequencing (NGS) into clinical molecular diagnostic (MolDx) laboratories has been growing and continues to expand into new applications for molecular oncology, but is hampered by technical challenges. In order to better meet the needs of diagnostic testing, it is necessary to understand the current and planned adoption of NGS systems as kits, both commercial and laboratory developed, must be optimized for specific machines.


We surveyed >3000 labs throughout Western Europe and will here focus on NGS usage in general and overall molecular methods for BRCA, BRAF, RAS, and EGFR in Germany (DE), Italy (IT), and the UK. Telephone interviews were conducted in 2015 and 2016 with data collected on technologies, systems and kits used, test volumes, and planned NGS systems and markers in the next 5 years.


Usage of NGS systems is increasing, though this varies by country, with DE being slowest to adopt where only 7% of MolDx labs have an NGS and 50% of systems used for oncology MolDx are still Sanger sequencers. Most molecular oncology done in IT is on RT-PCR (51%) systems, followed by NGS (34%). The UK has the highest NGS usage for oncology (52% of systems). Overall, ∼17% of MolDx labs in Europe have an NGS machine and, of those not currently running NGS, another 21% plan to acquire it in the next 5 years. Sixty-five percent of those reporting a preference chose Illumina systems. There is a growing focus on benchtop sequencers seen in the dominant presence of Illumina's MiSeqs (35%) and Thermo Fisher Ion sequencers (29%) out of all current NGS systems and future planned systems (90% reporting intent to acquire Illumina systems stated this would be a MiSeq).


Current top molecular oncology testing includes EGFR, BRAF, RAS, and BRCA and these will remain widely tested in the near future along with increasing use of multi-gene panels. The popularization of smaller and easier to use NGS systems will help grow clinical NGS usage as they're cheaper and faster but there is still a need for increased automation, more panels, and easier result reporting. As NGS usage in labs becomes standardized and more requested by oncologists, this will push payers to improve reimbursement strategies allowing for improved clinical patient care.

Clinical trial identification

Legal entity responsible for the study

dii Healthcare GmbH: a consulting and market research firm operating solely in the area of in-vitro diagnostics


dii Healthcare GmbH: a consulting and market research firm operating solely in the area of in-vitro diagnostics


All authors have declared no conflicts of interest.